RX BioSyent Inc.

12.23USD17.49 CAD · TSXV-1.58%Mkt Cap: 137.33M USDP/E: 20.58

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the…

Insiders, last 90 days3 buys
Institutional holders4 on file

Key Statistics

Company
Market Cap137.33M USD
Enterprise Value129.13M USD
Revenue (TTM)44.42M USD
Gross Profit23.04M USD
Net Income (TTM)6.30M USD
Revenue/Share3.92 USD
Last Price12.23 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA0906901081
Valuation
P/E (Trailing)20.58
P/E (Forward)31.23
PEG—
EV/EBITDA11.20
EV/Revenue2.91
P/S3.09
P/B4.25
EPS (TTM)0.59 USD
EPS (Forward)0.39 USD
52W Range
7.44588% of range12.86
52W High12.86 USD
52W Low7.445 USD
Profitability
Gross Margin76.57%
Oper. Margin21.52%
EBITDA Margin25.96%
Profit Margin20.93%
ROE21.73%
ROA18.23%
ROIC62.07%
ROCE26.79%
Growth
Revenue Growth64.30%
Earnings Growth6.40%
Cash Flow & Leverage
Operating CF6.30M USD
CapEx (TTM)272.49K USD
FCF Margin20.44%
FCF Yield6.61%
Net Debt-9.08M USD
Net Debt/EBITDA-0.79
Net Debt/FCF-1.00
Balance Sheet
Debt/Equity0.02
Current Ratio1.99
Quick Ratio1.33
Book Value/Sh2.88 USD
Cash/Share0.99 USD
Dividends
Fwd Div Rate0.15 USD
Trail. Div Rate0.03 USD
Div. Yield1.24%
5Y Avg Yield1.41%
Payout Ratio24.59%
Ex-Div DateAug 31, 2026
Pay DateSep 15, 2026
Analyst Consensus
Rating—
Target (Mean)12.58 USD
Upside (mean)+2.9%
Target Range12.58 USD – 12.58 USD
# Analysts1
Ownership
Shares Out.11.23M
Float9.14M
Insiders39.56%
Institutions4.15%
Short Interest
Short Ratio0.2d
Short % Out.0.01%
Shares Short1.58K
Short (prev mo.)2.02K
Technical
SMA 5011.75 (+4.0%)
SMA 20010.66 (+14.7%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)7.32K
Avg Vol (10d)6.25K
Technical Indicators
RSI (14)53.4
MACD0.3398
MACD Signal0.3596
MACD Hist.-0.0198
BB Upper12.87 USD
BB Middle12.17 USD
BB Lower11.46 USD
BB Width11.57%
ATR (14)0.2860 USD
Vol Ratio (20d)0.20x

About BioSyent (CVE: RX)

›

BioSyent (CVE: RX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.

The shares were at 17.49 CAD on 19 November 2026, up 63.2% over 52 weeks. Its 52-week range is 10.65 CAD to 18.40 CAD: the price is 4.9% below the high and 64.2% above the low.

At a market capitalisation of 196.45M CAD, it trades at 20.6 times trailing earnings and 31.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 17% for RX. It pays a dividend yielding 1.24% (it pays out 25% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

BioSyent reports return on equity of 21.7%, an operating margin of 21.5% and revenue up 64.3% year over year.

It holds more cash than debt, a net cash position of 12.98M CAD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 18.00 CAD is 2.9% above the current price.